Last updated on April 20, 2014 at 17:20 EDT

New Findings of Daily Consumption of Soy Isoflavones and Cacao-Flavonoids in Diabetes Type 2 Patients

May 4, 2012

ZURICH, May 4, 2012 /PRNewswire/ –

A new, one-year, double-blind controlled clinical study shows that cacao-flavonoids
and soy isoflavones can significantly improve biomarkers of CVD risk in postmenopausal
women with type 2 diabetes[1].

The trial, conducted by Peter J. Curtis, Ph.D., et al, funded by a UK based Charity,
Diabetes UJK, and supported by Frutarom Ltd., Israel, and Barry Callebaut, the world’s
leading manufacturer of high-quality cocoa and chocolate products, was published February,
2012, in Diabetes Care. The purpose of the study was to assess the effect of dietary
flavonoids on cardiovascular disease (CVD) risk in postmenopausal women with type 2
diabetes on established statin and hypoglycemic therapy.

The clinical trial consisted of 93 medicated postmenopausal women with type 2
diabetes. Subjects were randomly allocated to consume 27 g/day (split dose) of
flavonoid-enriched chocolate (Barry Callebaut ACTICOA(TM) chocolate containing 850 mg
flavan-3-ols [90 mg epicatechin] and 100 mg of isoflavones [aglycone equivalents)]/day) or
a matched placebo.

At the conclusion of this trial, the combined one-year intervention with flavan-3-ols
and isoflavones resulted in a significant improvement in biomarkers of CVD risk in
postmenopausal type 2 diabetic patients, compared to placebo. These data highlight the
additional benefit of dietary flavonoids to standard drug therapy in managing CVD risk in
this group of patients.

“We are incredibly happy with the new study results showing that the soy isoflavones
in SoyLife(R), produced by Frutarom, in combination with cacao-flavonoids could help
decrease CVD risk,” says Mira Koppert, Manager of the LifeLine brand extension at
Frutarom. “We anticipate these outstanding findings will open new opportunities in
marketing SoyLife to supplement makers and food processors and position it as the leading
soy isoflavones source in the global market.”

SoyLife has been included in more than 35 proprietary studies in the fields of
menopause, bone health, heart health, and cognitive function. “SoyLife stands out in the
market in comparison to other soy isoflavones, not only due to its extensive research but
also because it is a natural, multi-component ingredient, derived from soy germ,
containing not just soy isoflavones but also vitamin E, antioxidants, fibre and many
others,” explains Mira Koppert. “These factors and the typical soy germ isoflavone profile
of genistein : daidzein : glycitein, which is 15 : 50 : 35 indicate SoyLife is a perfect
solution to obtain the health effects associated with soy.” SoyLife is available in
concentrations ranging from 3% to 40% and can be used in tablets, capsules, soft-gel
capsules, as well as multiple functional food and beverage applications. For more
information, visit the new SoyLife website at http://www.soylife.com

About Frutarom

Frutarom’s vision is to become the preferred partner for tasty and healthy success,
reflecting its commitment to deliver the most flavorful and healthful solutions to our
customers. Frutarom sees research and innovation as a core competency and its global R&D
team benefits from a wealth of experience accumulated over 75 years. The company has the
distinct advantage of a broad range of in-house raw materials and close collaborations
with universities, research institutes and start-ups.

Meet us at VitaFoods booth no. 2134 & SupplySide MarketPlace booth no. 327

For further information, please contact:

        Company contact

        Health Business Unit
        Frutarom Switzerland Ltd.
        Mira Koppert
        Product Manager LifeLine
        Tel +41-44-782-6572
        Frutarom Switzerland Ltd., 8820 Wadenswil
        Email: Marketing_Health@Frutarom.com
        Web: http://www.frutarom.com

        Press Contact

        Liat Simha
        Tel: +972-3-9381107
        E-mail: ls@market-targets.com

1. Curtis P. J. et al, Chronic Ingestion of Flavan-3-ols and Isoflavones Improves
Insulin Sensitivity and Lipoprotein Status and Attenuates Estimated 10-Year CVD Risk in
Medicated Postmenopausal Women With Type 2 Diabetes, Diabetes Care 2012, 35, 226 – 232.

SOURCE Frutarom Industries Ltd

Source: PR Newswire